Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2024 | SERENA-1 Parts K/L: camizestrant and ribociclib in ER+/HER2- breast cancer

Richard Baird, MD, PhD, University of Cambridge, Cambridge, UK, discusses findings from Parts K and L of the Phase I SERENA-1 trial (NCT03616587), evaluating camizestrant, a next-generation oral selective estrogen receptor degrader (SERD), with ribociclib in ER+/HER2- advanced breast cancer. Initial efficacy was observed and the combination was well-tolerated, aligning with known safety profiles of each drug. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.